This version is for browsers with a low level of support for CSS, and is des

Biotechnology and Life Sciences in Baden-Württemberg

Logo state of Baden-Württemberg

Home Language Selection

Home Content Area

Home Navigator

You are here:

End Navigator


Internationalization is firmly anchored in the company DNA

The establishment of a subsidiary in London in 2004 heralded the presence on the international market of Konstanz-based GATC, which now has subsidiaries in England, France and Sweden comprising a total of 22 sales offices and laboratories. Twenty-five of the company’s 150 or so employees work in production and sales outside Germany. Peter Pohl, CEO of Europe’s leading provider of DNA services, explains in the following interview what he considers to be the key issues when entering international markets.

Photo of Peter Pohl, CEO GATC Biotech AG
Peter Pohl, CEO GATC Biotech AG (© GATC Biotech AG)

Mr. Pohl, what were the reasons that led to your company entering the international marketplace?

Going international is an important building block in the growth strategy we've been pursuing ever since the establishment of GATC Biotech. A broad base of regular customers and partners has developed in different locations in Europe over time to whom we wished to be closer than we had been before, and I believe that this was the major contributory factor in our decision to expand our business activities to other European locations. We therefore decided to establish a subsidiary in England, for example, which was one of our business activities hotspots where we had many project partners. When we started to think about setting up a subsidiary in England, we analysed our market opportunities and carried out studies on the price structures for our services. In addition, our presence at global trade fairs is an important tool that we use to look for attractive markets and new locations. As things stand today, we have a presence at around 80 life sciences and biotechnology congresses, symposia and trade fairs.

Were you faced with any country-specific differences which meant you had to adapt your activities accordingly? Did you have to take into account specific legal guidelines and conditions?

Yes we did as a matter of fact. The conditions in the different countries and markets differed considerably. But we were nevertheless able to come to a decision quite quickly to set up a subsidiary in London. And this was mainly because we knew the market potential from our experience in day-to-day business with English partners and customers. The decision to establish our Swedish subsidiary took more time. Initially, we evaluated and assessed which of the Scandinavian countries offered us the best possible infrastructure. The legal conditions in the countries where we wanted to set up subsidiaries were of minor importance as the conditions relating to our major business area, i.e. the sequencing of DNA, are very similar all over Europe.

Was it important to you whether the countries offered an attractive research and industry landscape?

When setting up a subsidiary abroad it is indeed important to know if we are likely to find an attractive environment that suits our business activities. Our market is in exactly the same place where research is being carried out. For this reason, we concentrate on markets with an excellent research infrastructure. And such markets can be found in metropolitan centres such as London or Paris. We focus on these markets and continue expanding from there.

GATC Biotech is known for equipping its facilities with the latest developments. What about your subsidiaries? Do they also continuously expand their pool of equipment?

Our most modern tools and cutting-edge technologies such as next-generation sequencing are currently only used in our Konstanz laboratories. Our London and Düsseldorf laboratories use devices that are based on the classical Sanger sequencing technology which we use for our overnight sequencing services. We will also apply the next-generation sequencing technologies in our subsidiaries once we are able to use them to reduce the time it takes to create sequences. We expect that this will happen within the next two years or so. However, I'd like to add that our laboratories in London and elsewhere work according to the same quality and automation standards as our central laboratory in Konstanz.


Peter Pohl studied administrative sciences at the University of Konstanz. He is co-founder (1990) and CEO of GATC Biotech AG. He also co-founded the GATC subsidiary LifeCodexx AG and served as its CEO between 2008 and 2009. He has been chairman of the LifeCodexx supervisory board since 2010. Peter Pohl has been a member of the BioDeutschland e.V. board of directors since 2005 and a board member of BioLAGO e.V. since 2007.

A contribution from:
Logo Region BioLago
Michael Statnik - 10.10.2011
© BIOPRO Baden-Württemberg GmbH



for Companies and Research Institutions



All biological terms with explanation